Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters

Role of regulators in safe prescribing of opioids

Heidi M. Oetter
CMAJ September 18, 2017 189 (37) E1195; DOI: https://doi.org/10.1503/cmaj.733125
Heidi M. Oetter
Registrar and CEO, College of Physicians and Surgeons of British Columbia, Vancouver, BC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

In their commentary, while appropriately advocating for increased resources to assist people living with chronic pain, Drs. Furlan and Williamson assert that regulators will “… need to be made aware that there is a small but definite role for the use of opioids in managing chronic noncancer pain, and that over-regulating prescribers so they cannot undertake trials of safe and effective therapies would be unhelpful.”1

To be clear, medical regulators have never denied a “small but definite role” for opioids, nor have they interfered with competently conducted trials of therapy.

In our experience, patients often overvalue opioids, benzodiazepines, anticonvulsants and other drugs commonly used in this context. Physicians are naturally affected by their patients’ suffering and may feel compelled to accede to demands for medically inappropriate prescribing. Accordingly, safe prescribing for chronic noncancer pain is among the most challenging aspects of medical practice for patients and physicians alike. Most physicians are grateful for some assistance.

Many physicians adopted a more liberal approach to prescribing opioids and other potentially addictive drugs for chronic pain in the 1990s because, based largely on gratifying experience with palliative care and gross underestimates of the risk of addiction, they anticipated it would be both safe and effective.

About 15 years ago, medical regulators were among the first to recognize and respond to emerging harms. The 2010 Canadian guideline2 was started and funded by medical regulators. Since that time, the College of Physicians and Surgeons of British Columbia has worked with hundreds of registrants through various means (e.g., published policies and resources, telephone advice, correspondence, face-to-face reviews of prescribing profiles and educational events, both plenary and limited enrollment, in-house and in collaboration) to help them operationalize foundational principles most recently set out in a professional standard.3

Chronic pain and addiction are both medical conditions. The Canadian Medical Association Code of Ethics prohibits discrimination on the basis of medical condition,4 and regulators are very firm about asserting this obligation in communication with physicians.

The college receives complaints and reports reflecting various perspectives from patients, concerned family members, other physicians, pharmacists, coroners, social workers, insurers and law enforcement. In the past 25 years, none have been brought to discipline in BC. Physicians want to provide safe and effective care, which they owe to their patients. The college has no mandate or desire to punish them for this and has a shared interest in helping them acquire the skill and knowledge they require to prescribe safely.

The characterization of regulation reflected in this commentary suggests that the authors are making inaccurate assumptions about what regulators know and do. Developing standards and guidelines for safe prescribing is assuredly not “over-regulation.” This college has welcomed the new “Guideline for Opioid Therapy and Chronic Noncancer Pain,”5 which affirms and complements other policies and will assist us in our work with physicians (although we are disappointed that the guideline fails to highlight the serious and entirely avoidable risk associated with combining opioids with benzodiazepines, and other sedatives). The goal has never been to prohibit opioid therapy, only to make it safer. Our observation is that virtually every primary care physician continues to recognize the small but definite role in their practice.

Footnotes

  • Competing interests: None declared.

Reference

  1. ↵
    1. Furlan AD,
    2. Williamson OD
    . New Canadian guidance on opioid use for chronic pain: necessary but not sufficient. CMAJ 2017;189:E650–1.
    OpenUrlFREE Full Text
  2. ↵
    1. Furlan AD,
    2. Reardon R,
    3. Weppler C
    for the National Opioid Use Guideline Group. Opioids for chronic noncancer pain: a new Canadian practice guideline. CMAJ 2010;182:923–30.
    OpenUrlFREE Full Text
  3. ↵
    Professional standards and guidelines — Safe prescribing of drugs with potential for misuse/diversion. Vancouver: College of Physicians and Surgeons of British Columbia (CPSBC); 2016 (revised 2016 Oct. 28). Available: https://cpsbc.ca/files/pdf/PSG-Safe-Prescribing.pdf (accessed 2017 Aug. 11).
  4. ↵
    CMA code of ethics. Ottawa: Canadian Medical Association (CMA); 2015. Available: https://cma.ca/EN/Pages/code-of-ethics.aspx (accessed 2017 Aug. 11).
  5. ↵
    1. Busse JW,
    2. Craige S,
    3. Juurlink DN,
    4. et al
    . Guideline for opioid therapy and chronic noncancer pain. CMAJ 2017;189:E659–66.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 189 (37)
CMAJ
Vol. 189, Issue 37
18 Sep 2017
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Role of regulators in safe prescribing of opioids
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Role of regulators in safe prescribing of opioids
Heidi M. Oetter
CMAJ Sep 2017, 189 (37) E1195; DOI: 10.1503/cmaj.733125

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Role of regulators in safe prescribing of opioids
Heidi M. Oetter
CMAJ Sep 2017, 189 (37) E1195; DOI: 10.1503/cmaj.733125
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • Reference
  • Responses
  • Metrics
  • PDF

Related Articles

  • New Canadian guidance on opioid use for chronic pain: necessary but not sufficient
  • Response to “Role of regulators in safe prescribing of opioids”
  • PubMed
  • Google Scholar

Cited By...

  • Response to "Role of regulators in safe prescribing of opioids"
  • Google Scholar

More in this TOC Section

  • The denial of racism is racism itself
  • An expanded role for blood donor emerging pathogens surveillance
  • Beyond wastewater surveillance: refining environmental pathogen detection in the built environment
Show more Letters

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire